CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and ...

Dublin, Feb. 06, 2024 (GLOBE NEWSWIRE) -- The "Orally Disintegrating Tablet Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, ...

Rockville, MD, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Based on a new research report published by Fact.MR, the global orally disintegrating tablet market is poised to reach a valuation of US$ 24.45 billion ...

This article is part of PharmTech's supplement "API Synthesis and Formulation 2009." New drug-delivery technologies are often championed by contract manufacturing organizations. For new technologies ...

The US Food and Drug Administration (FDA) has approved an amphetamine extended-release orally disintegrating tablet (Adzenys XR-ODT) for the treatment of attention ...

Please provide your email address to receive an email when new articles are posted on . The FDA recently approved Adzenys XR-ODT for the treatment of attention ...

Zolmitriptan 2.5mg, 5mg; orange flavor; contains phenylalanine. Store Zomig Tablets and zolmitriptan orally disintegrating tablets at controlled room temperature, 20 - 25ºC (68 - 77ºF) [see USP].

MALVERN, Pa., Nov. 18, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo") announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today ...